Cargando…

Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study

BACKGROUND: In metastatic breast cancer (MBC) patients, randomised controlled trials evaluated Bevacizumab as first-line treatment showed improvements in tumour response rate and progression-free survival (PFS) when added to chemotherapy. In Morocco, we conducted an observational study to investigat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boulaamane, Lamiaa, Boutayeb, Saber, Errihani, Hassan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337253/ https://www.ncbi.nlm.nih.gov/pubmed/22439740 http://dx.doi.org/10.1186/1756-0500-5-162

Ejemplares similares

First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study
por: Aitelhaj, Meryem, et al.
Publicado: (2016)

Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients
por: Aitelhaj, Meryem, et al.
Publicado: (2013)

Male breast cancer: a report of 127 cases at a Moroccan institution
por: Bourhafour, Mouna, et al.
Publicado: (2011)

Estimation of the cost of treatment by chemotherapy for early breast cancer in Morocco
por: Boutayeb, Saber, et al.
Publicado: (2010)

Maladie de hodgkin et cancer colique secondaire: à propos d'un cas
por: Boulaâmane, Lamia, et al.
Publicado: (2011)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology
por: Rais, Ghizlane, et al.
Publicado: (2012)

Sarcomatoid Carcinoma of the Lung: A Model of Resistance of Chemotherapy
por: Ouziane, Imane, et al.
Publicado: (2014)

Use of Medicinal Plants by Cancer Patients Under Chemotherapy in the Northwest of Morocco (Rabat Area) : Cross-Sectional Study
por: El Orfi, Nadia, et al.
Publicado: (2022)

The Practice of Medical Oncology in Morocco: The National Study of the Moroccan Group of Trialist in Medical Oncology (EVA-Onco)
por: Boutayeb, Saber, et al.
Publicado: (2013)

The evolution of the socio-cultural and religious characteristics of cancer patients in Morocco: case of the National Institute of Oncology Rabat
por: Elkhalloufi, Fahd, et al.
Publicado: (2021)

Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution
por: Ismaili, Nabil, et al.
Publicado: (2010)

Metastatic ameloblastoma responding to combination chemotherapy: case report and review of the literature
por: Amzerin, Mounia, et al.
Publicado: (2011)

Breast cancer in moroccan young women: a retrospective study
por: Abahssain, Halima, et al.
Publicado: (2010)

Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
por: Lorusso, Vito, et al.
Publicado: (2020)

Neoadjuvant chemotherapy in well-differentiated fetal adenocarcinoma: a case report
por: Lkhoyaali, Sihame, et al.
Publicado: (2014)

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
por: Sun, Zhengwu, et al.
Publicado: (2020)

Physical activity in cancer care: barriers and interventions
por: Azemmour, Youness, et al.
Publicado: (2022)

Primary osteosarcoma of the breast: case report
por: Saber, Boutayeb, et al.
Publicado: (2008)

Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
por: Shingaki, Sumito, et al.
Publicado: (2020)

Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study
por: Isono-Taniguchi, Roze, et al.
Publicado: (2022)

New schedule of bevacizumab/paclitaxel as first‐line therapy for metastatic HER2‐negative breast cancer in a real‐life setting
por: Cannita, Katia, et al.
Publicado: (2016)

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
por: Fabi, Alessandra, et al.
Publicado: (2012)

The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer
por: Yin, Chenxi, et al.
Publicado: (2016)

Kaposi's sarcoma responding to topical imiquimod 5% cream: a case report
por: Benomar, Sophia, et al.
Publicado: (2009)

Bevacizumab in the treatment of HER2-negative breast cancer
por: Lorusso, Vito
Publicado: (2008)

Bevacizumab in HER2-negative inflammatory breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
por: Bartsch, Rupert
Publicado: (2021)

Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies
por: Yamamoto, Yutaka, et al.
Publicado: (2022)

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
por: Miles, D W, et al.
Publicado: (2013)

Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
por: Zielinski, Christoph, et al.
Publicado: (2016)

A Real‐World Multicentre Retrospective Study of Paclitaxel‐Bevacizumab and Maintenance Therapy as First‐Line for HER2‐Negative Metastatic Breast Cancer
por: Gamucci, Teresa, et al.
Publicado: (2016)

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
por: Sánchez-Rovira, P., et al.
Publicado: (2013)

Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
por: Haugen, Mads H., et al.
Publicado: (2021)

Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer
por: Salmi, Narimane, et al.
Publicado: (2014)

Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer
por: Urakçı, Zuhat, et al.
Publicado: (2023)

Quality of life of Moroccan patients on the palliative phase of advanced cancer
por: Ahlam, Aitouma, et al.
Publicado: (2019)

Tolerability profile of bevacizumab in metastatic colorectal cancer: about a Medical Department experience
por: Khmamouche, Mohamed Reda, et al.
Publicado: (2016)

Cancer patients and COVID-19 vaccination, from safety to protocol adherence: A real-life setting report
por: Lamtai, Haitam, et al.
Publicado: (2022)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
por: Xun, Xueqiong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cm7qc7biisml2c7vlrjm95o9jn